Search research articles
Contact Us
Filters
Showing results (61-70 of 68) with videos related to
Page
of 7
Sort By:
You have reached the last page of results.
This site can display upto 68 results.
JAMA Neurology
|
June 30, 2015
Brain Imaging and Blood Biomarker Abnormalities in Children With Autosomal Dominant Alzheimer Disease: A Cross-Sectional Study
Yakeel T Quiroz, Aaron P Schultz, Kewei Chen, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association
|
November 14, 2022
A public resource of baseline data from the Alzheimer's Prevention Initiative Autosomal-Dominant Alzheimer's Disease Trial
Eric M Reiman, Jeremy J Pruzin, Silvia Rios-Romenets, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association
|
February 1, 2022
Sex differences in cognitive resilience in preclinical autosomal-dominant Alzheimer's disease carriers and non-carriers: Baseline findings from the API ADAD Colombia Trial
Clara Vila-Castelar, Pierre N Tariot, Kaycee M Sink, et al.
Neuroimage. Clinical
|
July 12, 2021
PET evidence of preclinical cerebellar amyloid plaque deposition in autosomal dominant Alzheimer's disease-causing Presenilin-1 E280A mutation carriers
Valentina Ghisays, Francisco Lopera, Dhruman D Goradia, et al.
Nature Medicine
|
March 4, 2025
Smartwatch- and smartphone-based remote assessment of brain health and detection of mild cognitive impairment
Paul Monroe Butler, Jenny Yang, Roland Brown, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association
|
May 18, 2020
Baseline demographic, clinical, and cognitive characteristics of the Alzheimer's Prevention Initiative (API) Autosomal-Dominant Alzheimer's Disease Colombia Trial
Silvia Rios-Romenets, Francisco Lopera, Kaycee M Sink, et al.
The Lancet. Neurology
|
January 24, 2026
Safety and efficacy of crenezumab in cognitively unimpaired carriers of the PSEN1<sup>Glu280Ala</sup> mutation at risk for autosomal-dominant Alzheimer's disease in Colombia (API ADAD Colombia Trial): a phase 2, randomised, double-blind, placebo-controlled trial
Pierre N Tariot, Francisco S Lopera, Silvia Ríos-Romenets, et al.
The Lancet. Neurology
|
February 21, 2026
A path to preventing cognitive impairment due to Alzheimer's disease: initiatives beginning in the USA
Eric M Reiman, Robert C Alexander, Jessica B Langbaum, et al.
Page
of 7
Search research articles
Search
Showing results (61-70 of 68) with videos related to
Sort By:
Page
of 7
You have reached the last page of results.
This site can display upto 68 results.
JAMA Neurology
|
June 30, 2015
Brain Imaging and Blood Biomarker Abnormalities in Children With Autosomal Dominant Alzheimer Disease: A Cross-Sectional Study
Yakeel T Quiroz, Aaron P Schultz, Kewei Chen, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association
|
November 14, 2022
A public resource of baseline data from the Alzheimer's Prevention Initiative Autosomal-Dominant Alzheimer's Disease Trial
Eric M Reiman, Jeremy J Pruzin, Silvia Rios-Romenets, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association
|
February 1, 2022
Sex differences in cognitive resilience in preclinical autosomal-dominant Alzheimer's disease carriers and non-carriers: Baseline findings from the API ADAD Colombia Trial
Clara Vila-Castelar, Pierre N Tariot, Kaycee M Sink, et al.
Neuroimage. Clinical
|
July 12, 2021
PET evidence of preclinical cerebellar amyloid plaque deposition in autosomal dominant Alzheimer's disease-causing Presenilin-1 E280A mutation carriers
Valentina Ghisays, Francisco Lopera, Dhruman D Goradia, et al.
Nature Medicine
|
March 4, 2025
Smartwatch- and smartphone-based remote assessment of brain health and detection of mild cognitive impairment
Paul Monroe Butler, Jenny Yang, Roland Brown, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association
|
May 18, 2020
Baseline demographic, clinical, and cognitive characteristics of the Alzheimer's Prevention Initiative (API) Autosomal-Dominant Alzheimer's Disease Colombia Trial
Silvia Rios-Romenets, Francisco Lopera, Kaycee M Sink, et al.
The Lancet. Neurology
|
January 24, 2026
Safety and efficacy of crenezumab in cognitively unimpaired carriers of the PSEN1<sup>Glu280Ala</sup> mutation at risk for autosomal-dominant Alzheimer's disease in Colombia (API ADAD Colombia Trial): a phase 2, randomised, double-blind, placebo-controlled trial
Pierre N Tariot, Francisco S Lopera, Silvia Ríos-Romenets, et al.
The Lancet. Neurology
|
February 21, 2026
A path to preventing cognitive impairment due to Alzheimer's disease: initiatives beginning in the USA
Eric M Reiman, Robert C Alexander, Jessica B Langbaum, et al.
Page
of 7